Towards selectivity? Approaches to the design of new anti-tumour agents--II.
D006585:Altretamine / Q000494:pharmacology; D000596:Amino Acids / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002241:Carbohydrates / Q000494:pharmacology; D002614:Chelating Agents / Q000494:pharmacology; D003078:Colchicine / Q000494:pharmacology; D004396:Coloring Agents / Q000494:pharmacology; D003606:Dacarbazine / Q000494:pharmacology; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D004347:Drug Interactions; D004611:Ellipticines / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D037102:Lectins / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000494:pharmacology; D010447:Peptide Hydrolases / Q000494:pharmacology; D011034:Podophyllotoxin / Q000494:pharmacology; D011108:Polymers / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000596:Amino Acids; D000970:Antineoplastic Agents; D002241:Carbohydrates; D002614:Chelating Agents; D004396:Coloring Agents; D004611:Ellipticines; D005493:Folic Acid Antagonists; D037102:Lectins; D009607:Nitrosourea Compounds; D011108:Polymers; D003606:Dacarbazine; D004317:Doxorubicin; D010447:Peptide Hydrolases; D011034:Podophyllotoxin; D006585:Altretamine; D003078:Colchicine; D003630:Daunorubicin